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Introduction
Isovaleric acidaemia (IVA, MIM #243500) is an autosomal recessive inborn error of 
metabolism. It is caused by a defect in isovaleryl-CoA dehydrogenase, a mitochondrial 
matrix enzyme that catalyses the oxidation of isovaleryl-CoA to 3-methylcrotonyl-CoA 
in the leucine degradation pathway. Deficiency of this enzyme leads to an accumulation 
of isovaleryl-CoA and its toxic metabolites. Patients with IVA typically present during the 
neonatal period with acute encephalopathy, vomiting, dehydration, severe metabolic 
acidosis, and a disturbed mental status.1 Estimated to occur less frequently than other 
organic acidaemias, the reported incidence of IVA ranges from 1 in 250 000 to 1 in 62 500 
in non-Chinese populations,2,3 and is 1 in 360 000 in Taiwanese.1 One suspected case was 
reported in Hong Kong in 1997,4 but there have been no confirmed cases and the local 
incidence is largely unknown. To date, fewer than 40 mutations causing this rare condition 
have been reported worldwide and most have been point mutations or single-nucleotide 
insertions/deletions.1,5,6 Here we report a case of IVA in a Hong Kong Chinese neonate 
who was compound heterozygous for a novel 4-bp duplication together with a missense 
mutation known to be common in other Chinese populations. We also propose a possible 
cause of the duplication event. Furthermore, we conclude that the missense mutation is 
likely to be a founder mutation in the Chinese population and should be screened for in 
every case occurring in Hong Kong.
Case report
Our patient was the first child born to non-consanguineous ethnic Chinese parents. He 
was delivered uneventfully at 38 weeks’ gestation with a birth weight of 3.35 kg, was put on 
mixed feeding, and discharged home on day 3. Retrospectively, it was noted that he had 
been described as drowsy and feeding poorly since birth. He presented to the hospital on 
day 8 when his parents observed that he had dyspnoea and he was intubated on admission 
for respiratory distress. His level of consciousness had deteriorated and a characteristic 
disagreeable ‘sweaty feet’ odour was noted. Investigations revealed a high anion gap (20 
mmol/L) metabolic acidosis (pH 7.25), hyperammonaemia (214 μmol/L, reference range [RR], 
56-92 μmol/L), and hypocalcaemia with an ionised calcium level of 0.75 mmol/L (RR, 1.12-1.30 
mmol/L). Pancytopenia developed soon after, with his haemoglobin level dropping from 
168 to 121 g/L, platelet count from 101 x 109 /L to 10 x 109 /L, and neutrophil count from 1.1 x 
109 /L to 0.1 x 109 /L within 1 day. Urinary metabolite screening by gas chromatography–mass 
spectrometry detected significant hyperexcretion of isovalerylglycine, 3-hydroxyisovaleric 
acid, 4-hydroxyisovaleric acid, and methylsuccinic acid. Liquid chromatography–tandem 
mass spectrometry also detected extremely high C5-acylcarnitine levels (9.7 μmol/L; RR, 
0.04-0.22 μmol/L) together with a severe reduction in free carnitine level (8 μmol/L; 12-46 
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Isovaleric acidaemia is a rare inherited organic acidaemia associated with a characteristic 
odour in affected patients. Fewer than 40 causative mutations have been reported to date. 
We report a case in a Hong Kong Chinese neonate who presented with respiratory distress 
and acute encephalopathy requiring aggressive resuscitation and treatment. Residual gross 
motor developmental delay was still observed at the age of 16 months. The child was 
subsequently found to harbour a known missense mutation (c.A1199G [p.Y371C]) and a 
novel 4-bp duplication (c.1148_1151dupGCTA [p.Y355X]) in the IVD gene. We suggest that 
the former is a founder mutation in the Chinese population and propose an explanation 
for the duplication event. Strategies that may achieve early diagnosis and prompt treatment 
include raising awareness of this condition, implementation of a tandem mass spectrometry 
neonatal screening programme, and local acquisition of appropriate medications for these 
metabolic diseases.
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異戊酸血症是一種罕有的酸血症，患者一般會發出腳臭氣味。到目前
為止只發現少於40個致病基因變異。本文報告一名香港華籍嬰兒出現
呼吸窘迫症狀及急性腦部病變，需要積極急救與治療。他於16個月大
的時候仍有殘餘運動功能發展遲緩的情況，最後發現嬰兒的IVD基因
內有已知的錯義突變（c.A1199G〔p.Y371C〕）及新型的4-bp重複序
列（c.1148_1151dupGCTA〔p.Y355X〕）。我們認為這種錯義突變
正是華人患者的創造者突變。本文並為該重複序列提出闡釋。要早期
診斷並及時治療，必須提升對此病的認識，為新生兒提供串聯質譜檢
測的篩檢計劃，並且隨時預備合適的藥物醫治這種新陳代謝疾病。
異戊酸血症中IVD基因內的DNA多聚酶
alpha停滯位上的新型重複序列及華人患者的
創造者突變
μmol/L) and other acylcarnitines in his plasma. A 
diagnosis of IVA was made. Computed tomography 
of his brain revealed small cerebellar haematomata, 
up to 1.9 cm in size. Levocarnitine was started on day 
3 and parenteral nutrition supplying 0.5 g/kg/day of 
protein, 3 g/kg/day of lipids and 10% dextrose was 
given. The child was also given intravenous arginine 
and oral sodium benzoate, thiamine, riboflavin, 
and biotin. Double-volume exchange transfusions 
were performed 4 times within 24 hours aiming to 
eliminate the toxic isovaleric acid metabolites in 
his blood. The child responded gradually with both 
a clinical and haematological improvement. The 
specific treatment for IVA, L-glycine, was not available 
locally and thus had to be ordered urgently from 
Melbourne, Australia. It was given orally from day 
17, and the parenteral nutrition was replaced by an 
oral milk formula with low leucine content. Clinical 
improvement was observed and he was extubated on 
day 19. The odour quickly subsided and was absent 
at the time of his discharge on day 32. At 10 weeks 
he was clinically well and active, with social smiling 
yet hypotonic with a severe head lag. Gross motor 
developmental delay was still noted when he was 
followed up at the age of 16 months. At the age of 16 
months, a developmental assessment showed that he 
had normal cognitive function with a delay in gross 
motor aspects.
Mutation analysis
Informed consent was obtained from the parents 
for mutation analysis. Genomic DNA was extracted, 
using a QIAamp blood kit (Qiagen, Hilden, Germany), 
from peripheral whole blood taken from the patient 
and his parents. For the patient, all coding exons with 
the flanking intronic regions of the IVD gene were 
amplified (primer sequences, polymerase chain 
reaction [PCR] mixture components and cycling 
conditions available upon request). Both strands 
were sequenced using the amplification primers 
and BigDyeDeoxy terminator cycle sequencing 
reagents (Applied Biosystems, Foster City [CA], US). 
The sequencing reaction products were purified by 
Centri-Sep spin columns (Princeton Separations, 
Adelphia [NJ], US) and detected on an ABI PRISM 
3100 Genetic Analyzer (Applied Biosystems).
 Compound heterozygosity was demonstrated 
by sequencing the PCR product of exon 12 with 
primers specific to wild-type and mutated missense 
sequences (5’-GGTCCCAGCCCCTATCTCAT-3’ and 
5’-GGTCCCAGCCCCTATCTCAC-3’ respectively) 
annealing to the missense mutation site (Fig). 
Results
Two different mutations in exon 12, c.A1199G 
(p.Y371C) and c.1148_1151dupGCTA (p.Y355X) 
were found in this patient. The former is a known 
disease-causing mutation but the latter has not been 
(a)
(b)
(c)
FIG. Segregation of the two mutations was demonstrated by 
sequencing with different primers
The duplication and missense mutation were detected on 
different alleles. Reverse complementary sequences are shown. 
(a) Sequenced with reverse amplification primer. Both mutations 
c.A1199G (left) and c.1148_1151dupGCTA (right) appeared 
to be heterozygous in the patient. (b) Sequenced with primer 
5’-GGTCCCAGCCCCTATCTCAC-3’ (a primer annealing to 
c.A1199G). The allele without duplication is shown. (c) Sequenced 
with primer 5’-GGTCCCAGCCCCTATCTCAT-3’ (a primer 
annealing to wild-type c.A1199). c.1148_1151dupGCTA is shown
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reported before. No other unreported variation was 
detected in any IVD exon. The patient’s father was 
found to be heterozygous for the missense mutation, 
and his mother was found to be heterozygous for the 
duplication.
 By sequencing the PCR product of exon 12 
with sequencing primers specific to wild-type and 
mutated missense sequences respectively, the two 
alleles were separated. It was shown that c.A1199G 
and c.1148_1151dupGCTA were on different alleles in 
this patient (Fig).
Discussion
While IVA is rare, early recognition and institution of 
treatment to remove toxic isovaleric acid is crucial 
to the outcome. We are presenting this case to alert 
clinicians to this disease. Our patient demonstrated 
classical IVA features: pancytopenia, hypocalcaemia, 
acidosis, and hyperammonaemia. The characteristic 
‘sweaty feet’ odour should enable this condition to 
be easily recognised clinically. The advent of this 
case has made L-glycine available in Hong Kong, 
so new patients should benefit from this specific 
treatment, which combines with isovaleric acid to 
form isovalerylglycine, thus providing an alternate 
pathway for excreting the toxic metabolites.
 Patients with IVA presenting with 
encephalopathy are at risk of adverse neurological 
outcomes due to the neurotoxicity of the metabolites.7 
An established neonatal screening programme could 
have detected this case before encephalopathy set 
in. Early institution of dietary and medical treatments 
could also have prevented his encephalopathy. This 
is supported by the experience of the tandem mass 
spectrometry neonatal screening programme in 
Taiwan.8
 The missense mutation c.A1199G in IVD is a 
known disease-causing mutation and was a common 
finding in a previous study in Taiwan.1 Its detection in 
our patient also suggests that it is a founder mutation 
in ethnic Han Chinese that is likely to be detected 
in other Chinese patients. On the other hand, 
c.1148_1151dupGCTA, which produces a premature 
termination codon at the site of duplication in a strictly 
conserved region, has not been reported before. It 
is predicted that the resulting protein truncation will 
cause partial loss of the fatty-acyl binding pocket of 
IVD and therefore direct disruption of the catalytic 
function of the enzyme.9
 Cooper and Krawczak10 pointed out that an 
insertional mutation involving a sequence of less 
than 10-bp in a gene-coding region is non-random 
and highly dependent upon the local DNA sequence 
context. Although insertions occur much less 
frequently than deletions, in principle they actually 
arise through similar mechanisms. Krawczak and 
Cooper11 described a consensus sequence closely 
resembling DNA polymerase alpha arrest sites. 
They proposed that the arrest of DNA synthesis at 
the replication fork underlies both deletional and 
insertional mutagenesis,10,11 possibly by increasing 
the probability of replication slippage errors or 
secondary structure formation. Many different 
insertions and deletions have been found to be 
associated with this consensus sequence TGRRKM. 
In our case, it was noted that TGGCTA (or TGTAGC 
on the reverse strand) at the site of duplication 
closely resembled the consensus sequence. It was 
thus likely that the duplication event occurred at this 
site when DNA synthesis was arrested in exon 12 in 
IVD.
 In our case, both mutations were located in 
exon 12 of IVD (Fig). Compound heterozygosity 
is often confirmed by analysing parental samples. 
When two heterozygous mutations are located 
in close proximity, eg in the same exon, as in our 
patient, segregation of the two mutations on separate 
chromosomes can also be demonstrated by using 
wild-type/mutation-specific sequencing primers 
annealing to the site of one of the mutations. In cases 
of compound heterozygosity, sequencing with the 
former primer (ie 5’-GGTCCCAGCCCCTATCTCAT-3’) 
shows the other mutation (ie c.1148_1151dupGCTA), 
and sequencing with the latter primer (ie 
5’-GGTCCCAGCCCCTATCTCAC-3’) shows the
absence of the other mutation. This approach is 
much simpler, more economical and time-saving 
than the traditional microsatellite analysis, in which 
multiple additional primers and amplification steps 
are required.
 In summary, we report a genetically confirmed 
case of IVA in a Hong Kong Chinese neonate who 
presented with respiratory distress and acute 
encephalopathy, with cerebellar haemorrhages 
evident on imaging. Mutation analysis served to 
confirm the diagnosis and enable DNA-based 
prenatal diagnosis in future pregnancies. It also 
provided new insights concerning the mutational 
spectrum in IVD. In Chinese patients, the proposed 
founder mutation, c.A1199G, should be screened 
for first, enabling simpler mutation analysis. Allele 
segregation was demonstrated by using wild-type/
mutation-specific sequencing primers, a simple and 
economical method compared with the traditional 
microsatellite analysis. The long-term neurological 
sequelae suffered by this patient may have been 
prevented by increased awareness, a tandem mass 
spectrometry–based neonatal screening programme, 
and local availability of the target medication for this 
rare metabolic disease.
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